このエントリーをはてなブックマークに追加
ID 30759
JaLCDOI
FullText URL
Author
Saika, Takashi
Tsushima, Tomoyasu
Nagai, Atsushi
Yokoyama, Teruhiko
Abarzua, Fernando
Ebara, Shin
Manabe, Daisuke
Abstract

We evaluated the efficiency and toxicity of estramustine phosphate (ECT), ifosfamide (IFM) and cisplatin (CDDP) combination chemotherapy in twenty-one patients with hormone-refractory prostate cancer (HRPC), for which there is currently no effective treatment. Patients received a daily dose of 560 mg ECT in combination with 1.2 g/m2 IFM on days 1 to 5 and 70 mg/m2 CDDP on day 1. This combination therapy was given every 3 to 4 weeks. An objective response of more than 50% reduction in prostate-specific antigen was observed in 9 of 18 patients (50%), and a more than 50% reduction in bi-dimensionally measurable soft-tissue lesions was observed in 2 of 7 patients (29%). The median duration of response among the cases showing partial response was 40 weeks, while the median duration of response of overall partial-response plus stable cases was 30 weeks. The median survival duration of all cases was 47 weeks. Toxicity was modest and acceptable. In conclusion, the ECT, IFM and CDDP combination chemotherapy regimen is a viable treatment option for HRPC. However, in comparison with our previous chemotherapy regimen of IFM and CDDP, no additional long-lasting effects resulting from the inclusion of ECT could be affirmed.

Keywords
hormone-refractory prostate cancer
chemotherapy
estramustine phosphate
ifosfamide
cisplatin
Amo Type
Article
Published Date
2006-02
Publication Title
Acta Medica Okayama
Volume
volume60
Issue
issue1
Publisher
Okayama University Medical School
Start Page
43
End Page
49
ISSN
0386-300X
NCID
AA00508441
Content Type
Journal Article
language
英語
File Version
publisher
Refereed
True
PubMed ID
Web of Sience KeyUT